Early detection of clinical benefit in patients receiving new cancer medicines allows for the rapid recruitment and refinement of clinical trial participants who demonstrate the strongest responses.
Leveraging the best available science focuses on patients most likely to benefit from new medicines. Phase I oncology trials are now efficacy studies and recruitment of potentially target-sensitive patients using advanced analytics, and the early detection of clinical response, allows companies to potentially move from escalation to efficacy determination in as little as 16 months.